173 related articles for article (PubMed ID: 16050273)
1. Drug-induced QT interval prolongation--regulatory guidance and perspectives on hERG channel studies.
Shah RR
Novartis Found Symp; 2005; 266():251-80; discussion 280-5. PubMed ID: 16050273
[TBL] [Abstract][Full Text] [Related]
2. hERG subunit composition determines differential drug sensitivity.
Abi-Gerges N; Holkham H; Jones EM; Pollard CE; Valentin JP; Robertson GA
Br J Pharmacol; 2011 Sep; 164(2b):419-32. PubMed ID: 21449979
[TBL] [Abstract][Full Text] [Related]
3. Reducing QT liability and proarrhythmic risk in drug discovery and development.
Valentin JP
Br J Pharmacol; 2010 Jan; 159(1):5-11. PubMed ID: 20141515
[TBL] [Abstract][Full Text] [Related]
4. ICH S7B In Vitro Assays Do Not Address Mechanisms of QT
Wu WW; Choe M; Johannesen L; Vicente J; Bende G; Stockbridge NL; Strauss DG; Garnett C
Clin Pharmacol Ther; 2023 Dec; 114(6):1332-1341. PubMed ID: 37702218
[TBL] [Abstract][Full Text] [Related]
5. Prediction of Thorough QT study results using action potential simulations based on ion channel screens.
Mirams GR; Davies MR; Brough SJ; Bridgland-Taylor MH; Cui Y; Gavaghan DJ; Abi-Gerges N
J Pharmacol Toxicol Methods; 2014; 70(3):246-54. PubMed ID: 25087753
[TBL] [Abstract][Full Text] [Related]
6. Iatrogenic QT Abnormalities and Fatal Arrhythmias: Mechanisms and Clinical Significance.
Cubeddu LX
Curr Cardiol Rev; 2009 Aug; 5(3):166-76. PubMed ID: 20676275
[TBL] [Abstract][Full Text] [Related]
7. Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives.
Shah RR
Br J Pharmacol; 2010 Jan; 159(1):58-69. PubMed ID: 19563537
[TBL] [Abstract][Full Text] [Related]
8. Effects of 4-Aminopyridine on Cloned hERG Channels Expressed in Mammalian Cells.
Renganathan M; Sidach S; Blight AR
Arch Drug Inf; 2009 Sep; 2(3):51-57. PubMed ID: 19915712
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 Management and Arrhythmia: Risks and Challenges for Clinicians Treating Patients Affected by SARS-CoV-2.
Carpenter A; Chambers OJ; El Harchi A; Bond R; Hanington O; Harmer SC; Hancox JC; James AF
Front Cardiovasc Med; 2020; 7():85. PubMed ID: 32432127
[TBL] [Abstract][Full Text] [Related]
10. New synthetic cannabinoids and the potential for cardiac arrhythmia risk.
Hancox JC; Copeland CS; Harmer SC; Henderson G
J Mol Cell Cardiol Plus; 2023 Dec; 6():100049. PubMed ID: 38143960
[TBL] [Abstract][Full Text] [Related]
11. Impact of antipsychotics and antidepressants drugs on long QT syndrome induction related to hERG channel dysfunction: A systematic review.
Nemati M; Hosseinzadeh Z; Nemati F; Ebrahimi B
Biochem Biophys Res Commun; 2023 Nov; 681():90-96. PubMed ID: 37774574
[TBL] [Abstract][Full Text] [Related]
12. The 'overly-sensitive' heart: sodium channel block and QRS interval prolongation.
Gintant GA; Gallacher DJ; Pugsley MK
Br J Pharmacol; 2011 Sep; 164(2):254-9. PubMed ID: 21488862
[TBL] [Abstract][Full Text] [Related]
13. Drug trapping in hERG K
Linder T; Bernsteiner H; Saxena P; Bauer F; Erker T; Timin E; Hering S; Stary-Weinzinger A
Medchemcomm; 2016 Mar; 7(3):512-518. PubMed ID: 28337337
[TBL] [Abstract][Full Text] [Related]
14. Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period.
Raschi E; Poluzzi E; Zuliani C; Muller A; Goossens H; De Ponti F
Br J Clin Pharmacol; 2009 Jan; 67(1):88-98. PubMed ID: 19076158
[TBL] [Abstract][Full Text] [Related]
15. Supporting an integrated QTc risk assessment using the hERG margin distributions for three positive control agents derived from multiple laboratories and on multiple occasions.
Leishman DJ; Brimecombe J; Crumb W; Hebeisen S; Jenkinson S; Kilfoil PJ; Matsukawa H; Melliti K; Qu Y
J Pharmacol Toxicol Methods; 2024 Jun; ():107524. PubMed ID: 38852689
[TBL] [Abstract][Full Text] [Related]
16. Avoiding hERG-liability in drug design via synergetic combinations of different (Q)SAR methodologies and data sources: a case study in an industrial setting.
Hanser T; Steinmetz FP; Plante J; Rippmann F; Krier M
J Cheminform; 2019 Feb; 11(1):9. PubMed ID: 30712151
[TBL] [Abstract][Full Text] [Related]
17. Chronic Administration of COVID-19 Drugs Fluvoxamine and Lopinavir Shortens Action Potential Duration by Inhibiting the Human Ether-à-go-go-Related Gene and Cav1.2.
Zheng Z; Cai D; Fu Y; Wang Y; Song Y; Lian J
Front Pharmacol; 2022; 13():889713. PubMed ID: 35873575
[No Abstract] [Full Text] [Related]
18. Deciphering Common Long QT Syndrome Using CRISPR/Cas9 in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Song Y; Zheng Z; Lian J
Front Cardiovasc Med; 2022; 9():889519. PubMed ID: 35647048
[TBL] [Abstract][Full Text] [Related]
19. An
Jin T; Hu B; Chen S; Wang Q; Dong X; Zhang Y; Zhu Y; Zhang Z
Front Pharmacol; 2018; 9():577. PubMed ID: 29904349
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive review of cardiovascular toxicity of drugs and related agents.
Mladěnka P; Applová L; Patočka J; Costa VM; Remiao F; Pourová J; Mladěnka A; Karlíčková J; Jahodář L; Vopršalová M; Varner KJ; Štěrba M;
Med Res Rev; 2018 Jul; 38(4):1332-1403. PubMed ID: 29315692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
